system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adiponectin, Adult, Aged, Alanine Transaminase, Blood Glucose, Body Mass Index, Body Weight, C-Reactive Protein, Diabetes Mellitus, Type 2, Exenatide, Fatty Liver, Female, Glycated Hemoglobin A, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Non-alcoholic Fatty Liver Disease, Peptides, Time Factors, Treatment Outcome, Venoms, Waist-Hip Ratio.
user
Does exenatide improve type 2 diabetes concomitant with non-alcoholic fatty liver disease? Context: To investigate the effects of exenatide on blood glucose, body weight and hepatic enzymes in patients with type 2 diabetes mellitus (T2DM) and concomitant non-alcoholic fatty liver disease (NAFLD). One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group. Patients were treated with exenatide and metformin, respectively, for 12 weeks. After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups. BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group.
assistant
Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD. Final Decision: yes